PHAR

NEUTRAL

$17.33 Live

Pharming Group N.V. · NASDAQ

Target $34.6 (+99.7%)

$8.05 52W Range $21.34

PHAR Pharming Group N.V. - Fundamental Analysis

NEUTRAL

Console Chart News

PHAR Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$17.33

Analyst Target

$34.6

+99.7% Upside

52W High

$21.34

52W Low

$8.05

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026

Market cap

$1.22B

P/E

433.25

ROE

1.0%

Profit margin

0.8%

Debt/Equity

0.42

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

PHAR presents a stark contrast between fundamental value and growth momentum, anchored by a stable Piotroski F-Score of 4/9. While the company exhibits explosive earnings growth (104.2% YoY) and a perfect recent track record of earnings beats, it trades at an extreme premium with a P/E of 433.25 and a Price/Book of 41.46. The massive divergence between the current price ($17.33) and the Graham Number ($0.61) indicates the market is pricing in aggressive future expansion rather than current assets. Despite strong analyst optimism and a 'strong_buy' consensus, the razor-thin profit margin (0.76%) leaves the company vulnerable to operational volatility.

Key Strengths

Exceptional gross margins (87.90%) typical of high-value biotech

Strong earnings growth trajectory (104.2% YoY) and consistent EPS surprises

Healthy liquidity position with a Current Ratio of 2.59

Low leverage with a Debt/Equity ratio of 0.42

Strong analyst conviction with a target price of $34.60

Key Risks

Extreme valuation risk (P/E 433.25) far exceeding sector averages

Critically thin net profit margins (0.76%) providing no room for error

Severe disconnect from defensive fair value (Graham Number $0.61)

Bearish technical trend (0/100) despite recent price appreciation

Low insider sentiment (40/100) suggesting lack of internal conviction at current levels

AI Fair Value Estimate

Based on comprehensive analysis

$12.5

-27.9% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Growth

Key drivers: Earnings acceleration, Valuation bubble risk, Strong liquidity

Confidence

90%

Value

15/100

Ref P/E, PEG, Graham Number

Positives

Forward P/E (47.22) is significantly lower than trailing P/E

Watchpoints

P/E of 433.25 is astronomical
Price/Book of 41.46 is extreme
Trades far above Graham Number ($0.61)

Future

88/100

Ref Growth rates

Positives

104.2% YoY Earnings Growth
4/4 recent quarters beating estimates
Strong analyst target price ($34.60)

Watchpoints

Sustainability of 600% Q/Q EPS growth is questionable

Past

75/100

Ref Historical trends

Positives

1Y price change of +114.2%
Consistent revenue growth (15%)

Watchpoints

Historical earnings volatility

Health

60/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Low Debt/Equity (0.42)
Strong Current Ratio (2.59)

Watchpoints

Piotroski F-Score of 4/9 is only 'Stable', not 'Strong'

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend payments
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$17.33

Analyst Target

$34.6

Upside/Downside

+99.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PHAR and closest competitors.

Updated 2026-04-16

Company	5Y	3Y	1Y	6M	1M	1W
PHAR Pharming Group N.V. Primary	+33.8%	+54.0%	+114.2%	+20.5%	+11.9%	+2.1%
MRVI Maravai LifeSciences Holdings, Inc. Peer	-91.0%	-76.8%	+85.3%	+1.6%	+4.1%	+13.5%
BLFS BioLife Solutions, Inc. Peer	-40.8%	-0.5%	-10.7%	+10.1%	-2.1%	+1.8%
IRMD IRADIMED CORPORATION Peer	+324.4%	+136.8%	+89.2%	+31.5%	-7.3%	-2.9%
ALVO Alvotech Peer	-65.9%	-71.8%	-66.2%	-52.0%	-17.7%	-1.6%

PHA

Pharming Group N.V.

Primary

+33.8%

+54.0%

+114.2%

+20.5%

+11.9%

+2.1%

MRV

Maravai LifeSciences Holdings, Inc.

Peer

-91.0%

-76.8%

+85.3%

+1.6%

+4.1%

+13.5%

BLF

BioLife Solutions, Inc.

Peer

-40.8%

-0.5%

-10.7%

+10.1%

-2.1%

+1.8%

IRM

IRADIMED CORPORATION

Peer

+324.4%

+136.8%

+89.2%

+31.5%

-7.3%

-2.9%

ALV

Alvotech

Peer

-65.9%

-71.8%

-66.2%

-52.0%

-17.7%

-1.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

433.25

47.22

N/A

41.46

3.25

32.16

305.36

$1.22B

Profitability

Profit margins and return metrics

Profit Margin 0.76%

Operating Margin 2.84%

Gross Margin 87.9%

ROE 1.02%

ROA 4.55%

Growth

Revenue and earnings growth rates

Revenue Growth +15.0%

Earnings Growth +104.2%

Q/Q Revenue Growth +14.89%

Q/Q Earnings Growth +86.4%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.42

Low debt

Current Ratio

2.59

Strong

Quick Ratio

1.97

Excellent

Cash/Share

$0.26

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$106.5B

Gross Margin

80.2%

Op. Margin

1.9%

Net Margin

5.0%

Total Assets

$0.5B

Liabilities

$0.2B

Equity

$0.3B

Debt/Equity

0.80x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

97%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-12

$0.07

+460.0% surprise

2025-11-06

$0.01

+122.2% surprise

2025-07-31

$0.01

+148.0% surprise

2025-05-08

$-0.02

+12.0% surprise

Healthcare Sector Comparison

Comparing PHAR against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)

P/E Ratio

433.25

This Stock

90.61

Sector Avg

+378.1% (Expensive)

Return on Equity (ROE)

1.02%

This Stock

-101.52%

Sector Avg

-101.0% (Below Avg)

Profit Margin

0.76%

This Stock

-12.47%

Sector Avg

-106.1% (Weaker)

Debt to Equity

0.42

This Stock

3.4

Sector Avg

-87.7% (Less Debt)

Revenue Growth

15.0%

This Stock

124.21%

Sector Avg

-87.9% (Slower)

Current Ratio

2.59

This Stock

4.56

Sector Avg

-43.3% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
PHAR Pharming Group N.V.	NEUTRAL	$1.22B	433.25	1.0%	0.8%	$17.33
MRVI Maravai LifeSciences Holdings, Inc.	NEUTRAL	$1.21B	-	-48.6%	-70.4%	$3.28	Compare
BLFS BioLife Solutions, Inc.	NEUTRAL	$1.2B	-	-5.2%	-3.2%	$24.87	Compare
IRMD IRADIMED CORPORATION	NEUTRAL	$1.19B	53.37	24.8%	26.8%	$93.4	Compare
ALVO Alvotech	BEARISH	$1.19B	16.61	-%	12.1%	$3.82	Compare

PHAR Pharming Group N.V.

NEUTRAL

Mkt Cap

$1.2B

P/E

433.2

ROE

1.0%

Price

$17.33

Compare with PHAR

BLFS BioLife Solutions, Inc.

Compare with PHAR

IRMD IRADIMED CORPORATION

Compare with PHAR

Compare with PHAR

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F

2026-04-02

PHAR filed its Form 20-F annual report on April 2, 2026. Due to the absence of provided excerpts, specific financial highlights and risk factors are unavailable for analysis.

20-F

2025-04-03

PHAR filed its 20-F annual report on April 3, 2025. Due to the absence of provided excerpts, specific financial highlights and risk factors are currently unavailable.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

STRONG_BUY

4 analysts

Canaccord Genuity

2026-04-10

init

Buy

HC Wainwright & Co.

2026-03-24

reit

Buy Buy

Oppenheimer

2026-03-13

reit

Outperform Outperform

Past News Coverage

Recent headlines mentioning PHAR from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

PHAR

PHAR Pharming Group N.V. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!